Royalty Pharma plc (RPRX) News
Track canonical SquawkNews coverage tagged to RPRX, Royalty Pharma plc. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
RPRX - Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
RPRX - Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
NEWS | Sep 15, 2026, 08:35 PM UTC
L
RPRX: Early target achievement and global expansion fuel strong growth and innovation in royalty funding
Surpassing its five-year capital deployment target early, the firm is leveraging new opportunities in Big Pharma and China, driving robust growth and innovation in R&D co-funding and synthetic royalties. Enhanced by a pr
GEOPOLITICS | Sep 14, 2026, 08:28 PM UTC
L
RPRX: Accelerated growth via innovative deals, AI-driven insights, and expanding global partnerships
Achieved capital deployment targets ahead of schedule, driven by robust deal flow and new opportunities in big pharma and China. Innovative R&D co-funding and synthetic royalty structures are fueling growth, while AI-pow
GEOPOLITICS | Sep 14, 2026, 07:34 PM UTC
H
Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus
Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets.On Friday, the Do
NEWS | Sep 13, 2026, 01:11 PM UTC
L
Royalty Pharma to present at upcoming investor conferences
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc NASDAQ:RPRX today announced that it will participate in the following upcoming investor conferences during the month of September:The webcast will be access
EQUITY | Sep 09, 2026, 08:11 PM UTC
L
Royalty Pharma maintained as Buy by TD Cowen
TD Cowen maintained its Buy rating on Royalty Pharma.
EQUITY | Sep 08, 2026, 02:23 PM UTC
L
RPRX - Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
RPRX - Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
EQUITY | Sep 04, 2026, 11:05 PM UTC
L
Stephens watchlist flags potential S&P Dow Jones September index changes
Stephens identified companies that could be added to, moved between, or removed from S&P Dow Jones Indices in the third-quarter rebalance after the close on Friday, September 18.
EQUITY | Sep 03, 2026, 04:05 PM UTC
M
RPRX: Royalty Pharma and Zealand Pharma Enter Funding Agreement
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
MNA | Aug 12, 2026, 08:10 PM UTC
L
RPRX - Royalty Pharma reports second quarter 2026 results
RPRX - Royalty Pharma reports second quarter 2026 results
EARNINGS | Aug 05, 2026, 11:01 AM UTC
L
RPRX Appoints Greg Raskin as SVP
RPRX appoints new Senior Vice President
EQUITY | Aug 03, 2026, 12:15 PM UTC
L
RPRX neurimmune sells a portion of its Royalty interest in cliramitug to Royalty Pharma Neurimmune: sold portion of its Royalty interest in
RPRX neurimmune sells a portion of its Royalty interest in cliramitug to Royalty Pharma Neurimmune: sold portion of its Royalty interest in cliramitug to Royalty Pharma for up to $425M - In Q1 of 2027, Royalty Pharma wil
EQUITY | Jul 22, 2026, 10:51 AM UTC